SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending due to strong community support and ongoing building efforts, including IRL initiatives and new product teases like KENDU SPICE. Community members express conviction and encourage others to join the movement, emphasizing KENDU's potential to become a major brand. Discussions also highlight the upcoming KENDU Games release and various merchandise offerings.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending amid speculation of a potential acquisition, especially after Pfizer's recent move in the obesity market, sparking discussions about Viking's value and potential suitors. Community members are debating the company's valuation, comparing its assets to competitors, and analyzing potential buyout scenarios. Discussions also include the impact of potential Medicare/Medicaid coverage on the obesity market and potential partnership.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SOUN is trending due to recent earnings, where revenue increased, and full-year outlook was raised, despite a mixed market reaction. The community is debating whether the current price reflects the company's long-term potential in the AI space, with discussions around profitability targets and potential market manipulation. Bullish sentiment remains as some highlight strong fundamentals, recent analyst upgrades, and future growth catalysts, while others express concern over the stock's performance relative to its sector.

Monero

Monero is gaining traction as community members emphasize its importance as a leading privacy coin, drawing comparisons to what Bitcoin was originally intended to be. Despite some exchanges delisting XMR, discussions highlight Monero's solid use case, adoption in certain markets, and potential for significant growth as privacy becomes more valued in the crypto space. The community believes Monero is undervalued and poised for a substantial move.

Dogelon Mars

Dogelon Mars is trending amidst mixed community sentiment, with some expressing frustration over price movement and unrealized gains, while others remain hopeful and accumulate more tokens. The community is closely watching for potential catalysts like a significant burn or metaverse integration, but some express concern over broken promises from the development team. General market volatility and influence from broader crypto trends are also being discussed.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

EOSE is trending as investors compare it to PLTR and IREN, anticipating a similar breakout. The company's recent collaboration and supply agreements are fueling optimism, with community members citing a large commercial pipeline. Discussions revolve around key resistance levels and potential for significant growth in the energy storage sector, particularly related to AI and hyperscalers.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as community members discuss its potential for a significant move, referencing its strong fundamentals and historical performance, while some traders point to technical indicators suggesting a possible breakout. Discussions also involve comparisons to other cryptocurrencies and speculation about a potential altcoin season. The community seems optimistic about Litecoin's long-term prospects and usage.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending amid reports of a potential breakup into two separate companies, focusing on sauces and condiments versus grocery products, which has sparked discussion about unlocking shareholder value. While some are skeptical, pointing to existing debt and margin concerns, others see an opportunity for strategic focus and growth, especially with the high dividend yield becoming more attractive amidst potential rate cuts. Community members are actively debating whether this split will truly benefit the stock or if it's simply rearranging a struggling business.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

OSCR is trending amidst speculation surrounding the extension of ACA subsidies and the potential impact on the company's future profitability, further fueled by mixed earnings reports in the healthcare sector. The stock exhibits high volatility, with community members debating whether to buy, sell, or hold, based on their outlook for ACA and the company's 2026 profitability guidance. Some traders are closely watching technical indicators for potential entry or exit points, while others are highlighting large institutional ownership as a bullish sign.

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, the TRICARE program, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

Centene Corp.

Centene Corp. is trending amid discussions around potential ACA subsidy extensions and the impact of a possible government shutdown on healthcare. Community members are weighing the implications of Trump's comments on healthcare and potential impacts on insurance companies, while also considering Centene's financial outlook and potential for growth in the sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Halper Sadeh LLC Encourages Applied Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Applied Therapeutics, Inc. (NASDAQ: APLT) breached their fiduciary duties to shareholders. If...

Retail buzz&nbsp;surrounding Applied Therapeutics Inc spiked&nbsp;late Sunday after the company revealed full 12-month clinical results alongside new 18- and 24-month topline data from&nbsp;a midstage trial of govorestat to treat Charcot-Marie-Tooth disease caused by Sorbitol Dehydrogenase deficiency (CMT-SORD).MRI observations showed that govorestat treatment slowed disease progression at 24 months, while keeping blood sorbitol levels low and improving functional outcomes and patient-reported metrics.The 12-month data revealed a statistically significant increase in the CMT-Health Index (CMT-HI) and a connection between sorbitol reductions and enhanced mobility and balance.&nbsp;CMT-SORD is a rare, progressive neuromuscular disorder that leads to nerve damage, muscle weakness, and mobility impairment.The company acknowledged that the primary endpoint of the 10MWRT at 12 months failed to show statistical significance, which led to its removal from the CMT-FOM clinical outcomes tool.Patients demonstrated good tolerance for govorestat, maintaining safety for two years.&nbsp;90% of eligible patients continued participating in the open-label extension study.&nbsp;Applied Therapeutics said it will submit a New Drug Application (NDA) for govorestat by 2025.The company’s shares surged 22.8% to close at $0.60 on Friday, with a further 1.2% gain in after-hours trading.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘a 629% surge in 24-hour message volume.Some retail traders expressed optimism about Applied Therapeutics' prospects, with one suggesting that the stock’s sharp decline in December may have been overdone and that the current low valuation presents a “monster opportunity.”<stembedurl>https://stocktwits.com/BuyThemCheapStackemDeep/message/615044473</stembedurl>Another pointed to the positive impact of govorestat on disease progression in CMT-SORD, noting that in a rare condition with no approved treatments, the available data could support regulatory approval.<stembedurl>https://stocktwits.com/Aawilliam2003/message/615043651</stembedurl>The stock has declined 33% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A photo illustration showing a mix of various tablets and pharmaceutical products, primarily manufactured by U.S. pharmaceutical companies, photographed in Edmonton, Alberta, Canada, on April 10, 2025 (Photo by Artur Widak/NurPhoto via Getty Images)

Retail Traders Cheer Applied Therapeutics Data On Rare Nerve Disease Drug

The company said that Govorestat slowed disease progression and improved patient outcomes in CMT-SORD, a rare hereditary neuropathy. The company plans to submit an NDA in 2025 amid strong retail investor interest.

Equity

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Applied Therapeutics

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Applied Therapeutics, Inc. (Applied Therapeutics or the Company) (NASDAQ: APLT) and reminds...

Class Action Filed Against Applied Therapeutics, Inc. (APLT) - February 18, 2025 Deadline to Join - Contact Levi & Korsinsky

Class Action Filed Against Applied Therapeutics, Inc. (APLT) - February 18, 2025 Deadline to Join - Contact Levi & Korsinsky Class Action Filed Against Applied Therapeutics, Inc. (APLT) - February...

INVESTOR DEADLINE TOMORROW: Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - APLT

INVESTOR DEADLINE TOMORROW: Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - APLT INVESTOR DEADLINE TOMORROW: Applied Therapeutics, Inc...

APLT Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Applied Therapeutics, Inc. (APLT) Investors of Filing Deadline in Class Action Lawsuit

APLT Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Applied Therapeutics, Inc. (APLT) Investors of Filing Deadline in Class Action Lawsuit APLT Deadline in 2 Days: Kessler Topaz...

APLT Deadline: APLT Purchasers Have Opportunity to Lead Applied Therapeutics, Inc. Securities Fraud Lawsuit

APLT Deadline: APLT Purchasers Have Opportunity to Lead Applied Therapeutics, Inc. Securities Fraud Lawsuit APLT Deadline: APLT Purchasers Have Opportunity to Lead Applied Therapeutics, Inc...

APLT Deadline: Rosen Law Firm Urges Applied Therapeutics, Inc. (NASDAQ: APLT) Investors to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities between...

Deadline Soon: Applied Therapeutics, Inc. (APLT) Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz reminds investors of the upcoming February 18, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of...

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

Applied Therapeutics Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

APLT
Applied Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest APLT News

APLTApplied Therapeutics Inc